PD184352 (CI-1040)

Catalog No.S1020

PD184352 (CI-1040) Chemical Structure

Molecular Weight(MW): 478.67

PD184352 (CI-1040) is an ATP non-competitive MEK1/2 inhibitor with IC50 of 17 nM in cell-based assays, 100-fold more selective for MEK1/2 than MEK5. Phase 2.

Size Price Stock Quantity  
In DMSO USD 140 In stock
USD 70 In stock
USD 120 In stock
USD 270 In stock
USD 670 In stock
USD 770 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 47 Publications

13 Customer Reviews

  • The inhibitor PD173074 (A) or PD184352 (B) was administered to one uterine horn of Hand2d/d mice on day 3 of pregnancy (n = 5). The other horn served as vehicle-treated control. Uterine horns were collected on the morning of day 4, and sections were subjected to IHC to detect p-FRS2, p-ERK1/2, and Ki-67. (C) IHC of pERa and Muc-1 in uterine sections of Hand2d/d mice treated with PD173074 or PD184352.

    Science 2011 331, 912-916. PD184352 (CI-1040) purchased from Selleck.

     

    Melanoma cell viability and in vivo growth by cyclindependent kinase 2/4 inhibition. Western blot analysis for c-Jun, phosphorylated-ERK1/2 (Thr202/Tyr204) (p-ERK1/2), and total ERK1/2 protein levels was done for human melanoma cell lines treated with the BRAFV600E inhibitor GDC-0879 (1 μM), or MEK inhibitors CI-1040 (1 μM), U0126 (1 μM), and PD98059 (10 μM) for 18 hours.

    J Natl Cancer Inst 2012 104(21), 1673-9. PD184352 (CI-1040) purchased from Selleck.

  •  

    Melanoma cell viability and in vivo growth by cyclindependent kinase 2/4 inhibition. In vivo growth of LOXIMVI xenografts in athymic nude Foxn1nu mice is shown. Tumors were allowed to grow to a maximum volume of 250 mm3, and the mice were subsequently treated daily at the indicated dose levels with CDK2/4 inhibitors by intraperitoneal injection in combination with a BRAFV600E- or MEK-inhibitor. CDK2/4 inhibitor (CVT-313/indolocarbazole CDK4-I) treatment sensitizes tumors to GDC-0879 and CI1040.

    J Natl Cancer Inst 2012 104(21), 1673-9. PD184352 (CI-1040) purchased from Selleck.

    LY294002 (10 μM for 12 h)- and PD184352 (10 μM for 12 h)-treated Her2-transfected DU145 and PC3 cells, respectively, showed reciprocal feedback inhibition between the PI3K/AKT and MEK/ERK path ways

    Proc Natl Acad Sci U S A 2011 108, 16392-7. PD184352 (CI-1040) purchased from Selleck.

  • a Expression and phosphorylation status of AKT and ERK1/2 and amount of cleaved CPP32 at 72 h after drug treatment were assessed by western blot. Actin was used to confirm equal protein loading. A representative experiment of three was reported. The panel shows cropped blots.

    J Hematol Oncol, 2017, 10(1):19. PD184352 (CI-1040) purchased from Selleck.

    The effect of CI-1040 on cell viability of molecular apocrine lines. MTT assay to measure cell viability in MDA-MB-453 cell line after treatment with CI-1040 (CI) at 2 to 25 μM concentrations. MTT assay to measure cell viability in HCC-1954 cell line after treatment with CI-1040 at 2 to 25 μM concentrations.

    Breast Cancer Res 2011 13, R36. PD184352 (CI-1040) purchased from Selleck.

  • Combination indices (CI) for flutamide (FLU) and CI-1040 combination therapy in MDA-MB-453-R line using MTT assay. Therapies were carried out with flutamide at 5 and 10 μM with each concentration of CI-1040 at 5 and 10 μM (CI-5 and CL-10). The concentrations of fluatmide and CI-1040 monotherapies with an effect similar to that of each combination therapy are depicted. Error bars: ±2SEM. Western blot analysis was used to measure the phosphorylated and total ERK levels in MDA-MB-453-R line following combination therapies with CI-1040 (5 μM)/flutamide (5 μM) and CI-1040 (5 μM)/flutamide (10 μM). RR values were measured relative to the untreated MDA-MB-453-R line.

    Breast Cancer Res 2011 13, R36. PD184352 (CI-1040) purchased from Selleck.

    Western blot analysis to measure the phosphorylated and total ERK levels in MDA-MB-453 and HCC-1954 cell lines after treatment with CI-1040 (CI) at 10-μM concentration.

     

     

    Neoplasia 2011 13, 154–166. PD184352 (CI-1040) purchased from Selleck.

  • Relative expression of AR using RT-PCR in MDA-MB-453 and HCC-1954 cell lines after treatment with CI-1040 (MEK Inh) at 10-μMconcentration for 24 hours. Expression is relative to that of vehicle-treated cells (CTL). *P < .01 is for CI-1040 versus control. Error bars,±2 SEMs.

     

     

    Neoplasia 2011 13, 154–166. PD184352 (CI-1040) purchased from Selleck.

    Synergistic effect of AR and mitogen-activated protein kinase kinase inhibitors on cell viability. (A) MTT assay to measure cell viability in MDA-MB-453 cell line after monotherapies and combination treatments with flutamide (FLU) and CI-1040 (CI) at 5 and 10 μΜ concentrations. CTL: control. Error bars: ±2 SEM. (B) Combination indices (CI) for flutamide and CI-1040 combination therapy in MDA-MB-453 cell line using MTT assay. Cell viability was measured after combination therapies with flutamide at 5 and 10 μM with each concentration of CI-1040 at 5 and 10 μM. The concentrations of FLU and CI-1040 monotherapies with an effect similar to that of each combination therapy are depicted. Error bars: ±2 SEM. (C) Combination indices for flutamide and CI-1040 combination therapy in HCC-1954 cell line using MTT assay. Cell viability was measured after combination therapies with flutamide at 20 and 40 μM with each concentration of CI-1040 at 5 and 10 μM. (D) Combination indices for flutamide and CI-1040 combination therapy in HCC-202 cell line using MTT assay at concentrations described in Figure 2C.

     

     

    Neoplasia 2011 13, 154–166. PD184352 (CI-1040) purchased from Selleck.

  • After starved in serum-free medium for 24h, Breast cancer cells incubated with the indicated concentrations of CI-1040 for 3h,followed by 15-minute stimulation of 100ng/ml EGF

     

     

    2010 Dr. Zhang of Tianjin Medical University. PD184352 (CI-1040) purchased from Selleck.

    After starved in serum-free medium for 24h, Breast cancer cells incubated with the indicated concentrations of CI-1040 for 3h,followed by 15-minute stimulation of 100ng/ml EGF

     

    2010 Dr. Zhang of Tianjin Medical University. PD184352 (CI-1040) purchased from Selleck.

  • The bar chart represents the relative numbers of third-round colonies of primary hematopoietic cells transduced with MLL-AF9 with treatment of compound PD184352 (CI-1040, 10 μM, a MEK inhibitor) and SB216763 (10 μM, GSK-3 inhibitor). The synergic effect between compounds CI-1040 and SB-216763 has been observed.

     

     

    2010 Dr. Shuo Dong of Baylor College of Medicine. PD184352 (CI-1040) purchased from Selleck.

Purity & Quality Control

Choose Selective MEK Inhibitors

Biological Activity

Description PD184352 (CI-1040) is an ATP non-competitive MEK1/2 inhibitor with IC50 of 17 nM in cell-based assays, 100-fold more selective for MEK1/2 than MEK5. Phase 2.
Features First MEK inhibitor to begin clinical development.
Targets
MEK1 [1]
(Cell-free assay)
MEK2 [1]
(Cell-free assay)
17 nM 17 nM
In vitro

CI-1040 treatment produces a reduction of pMAPK levels in multiple tumor cells including Colon 26, BX-PC3 pancreatic, A431 cervical, HT-29 colon, ZR-25-1 breast and SKOV-3 ovarian carcinomas. CI-1040 treatment doesn't inhibit the phosphorylation of Jun kinase, p38 kinase or Akt, indicating CI-1040 specifically targets MEK. Inhibition of MAPK activation by CI-1040 prevents cell cycle progression and induces a G1 block. [1] The IC50 for inhibition of MEK1 by CI-1040 is 0.3 μM, 15-fold higher than the concentration required to inhibit the EGF-induced activation of ERK2 in Swiss 3T3 cells. These results indicate CI-1040 exerts its effects on cells by suppressing the activation of MKK1, and not by blocking its activity. 2 nM PD184352 inhibits the activation of MKK1 in Swiss 3T3 cells by 50%, while over 100-fold concentration of CI-1040 inhibits MEK1 in vitro. PD184352 also inhibits the Raf-catalysed phosphorylation of MEK1 without any effect on the Raf-catalysed phosphorylation of myelin basic protein. [2] CI-1040 inhibits 86% of papillary thyroid carcinoma (PTC) cell growth with the RET/PTC1 rearrangement at 10μM compared with cells treated with DMSO only. CI-1040 shows potent inhibition to PTC cells (BRAF mutation) with GI50 of 52 nM, but low activity to RET/PTC1 rearrangement type with GI50 of 1.1 μM. [3] A recent research indicates CI-1040 increases the apoptotic effect of BMS-214662 in a CML blast crisis cell line, K562, and in primary chronic phase CD34+ CML cells. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
H9 MkDJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mkj4TWM2OD1yLkCyNlc3KM7:TR?= M3vZN3NCVkeHUh?=
CHP-212 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojNTWM2OD1yLkCyPFg2KM7:TR?= NUHPfYJrW0GQR1XS
EoL-1-cell M3;i[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTBwMESxOVIh|ryP NUnuWWpDW0GQR1XS
DU-4475 NX\iPZhbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nzTGlEPTB;MD6wO|U6QSEQvF2= MYrTRW5ITVJ?
MMAC-SF M3TiZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTBwMUC5O|Qh|ryP MVnTRW5ITVJ?
AGS MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV74NZBGUUN3ME2wMlEyPzF|IN88US=> MUnTRW5ITVJ?
M14 MkH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn:5TWM2OD1yLkG1OFY5KM7:TR?= M{PGWXNCVkeHUh?=
CP50-MEL-B NV3TRoNMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfMToZOUUN3ME2wMlE4OjV2IN88US=> MoP4V2FPT0WU
C32 NU[3VWJET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3ZNYhKSzVyPUCuNVkxPzJizszN NEfPS|BUSU6JRWK=
KMOE-2 NEXISXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTBwMUm3PVUh|ryP M3zzZXNCVkeHUh?=
A101D NY\zVnFIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rOWmlEPTB;MD6yNVQh|ryP MmfzV2FPT0WU
KM12 MnrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUW1cHRZUUN3ME2wMlI1ODV5IN88US=> MY\TRW5ITVJ?
HSC-4 Ml3ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTBwMkSzPVUh|ryP Mn3lV2FPT0WU
NOMO-1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTBwMkW3OFIh|ryP MVvTRW5ITVJ?
MZ7-mel NHfpXW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTBwMk[zOEDPxE1? NHS2b5VUSU6JRWK=
ACN MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTBwMk[3N|ch|ryP MorHV2FPT0WU
MEL-HO M2rDbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1S2UWlEPTB;MD6yO|Y2OiEQvF2= MlzpV2FPT0WU
BHT-101 NEPMU5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF[wXItKSzVyPUCuNlg3ODZizszN MWrTRW5ITVJ?
SK-MEL-28 NFP4VVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2S3SGlEPTB;MD6zNFQxQSEQvF2= NGDjS4lUSU6JRWK=
KG-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILIeYFKSzVyPUCuN|A3PjhizszN M1rienNCVkeHUh?=
COLO-679 M13CfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HiTGlEPTB;MD6zNlczKM7:TR?= NFrG[FdUSU6JRWK=
SK-MEL-24 NFKwV2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDCd4g{UUN3ME2wMlMzQDF|IN88US=> MU\TRW5ITVJ?
G-361 NUnSPWtjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTBwM{[3PVUh|ryP MmfaV2FPT0WU
KY821 MknhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2GyfWlEPTB;MD6zO|kyKM7:TR?= NVS1UWdMW0GQR1XS
KASUMI-1 M3uzR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILLO|ZKSzVyPUCuN|k6KM7:TR?= MlrqV2FPT0WU
HL-60 M{DHU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7zTWM2OD1yLkSxNVA4KM7:TR?= NXPBZoU6W0GQR1XS
K5 NHzWVGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLnNoZjUUN3ME2wMlQ{OTF5IN88US=> M{PQ[3NCVkeHUh?=
KU812 MofLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLiUFJzUUN3ME2wMlQ2Ojl7IN88US=> NWLuTopYW0GQR1XS
SH-4 NFjmVmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYT6UoRvUUN3ME2wMlQ3OjV4IN88US=> MmfsV2FPT0WU
HTC-C3 NV65O4xPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DSNGlEPTB;MD60OlU{OSEQvF2= M3\CWnNCVkeHUh?=
CP66-MEL MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDCTWM2OD1yLkS4PFA6KM7:TR?= NILHfWJUSU6JRWK=
WM-115 MmnBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3e1cmlEPTB;MD60PVI2PyEQvF2= MoHEV2FPT0WU
A2780 NX\LO2JNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HKXGlEPTB;MD60PVgzOyEQvF2= NIrlVphUSU6JRWK=
P12-ICHIKAWA M4j2Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoexTWM2OD1yLk[xNlIyKM7:TR?= MVHTRW5ITVJ?
HMV-II NV;RSphDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTBwNkS0OlUh|ryP MY\TRW5ITVJ?
HT-144 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrWOIpuUUN3ME2wMlY1PjV5IN88US=> MUfTRW5ITVJ?
LB2518-MEL NYPRT4h4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTBwN{G2N|Ih|ryP NGPSWI5USU6JRWK=
NCI-SNU-1 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTBwN{W0N|Mh|ryP MmT5V2FPT0WU
C2BBe1 NITte4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHtWWFKSzVyPUCuPFExOjNizszN NFT3[FJUSU6JRWK=
PSN1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvHR|dKSzVyPUCuPVYyQTZizszN MnvBV2FPT0WU
UACC-257 M1jHfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTBwOU[0O|Mh|ryP NHrZW4RUSU6JRWK=
RVH-421 M1PabGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjUTWM2OD1yLkm3NVgh|ryP MV\TRW5ITVJ?
GP5d NFLEXIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFyxWGpKSzVyPUCuPVg{ODhizszN M2C2[nNCVkeHUh?=
TYK-nu NIHoe|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTFwMEOxO|Ih|ryP MVTTRW5ITVJ?
SK-N-AS M2eySWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTFwMEe5OFch|ryP M1;tV3NCVkeHUh?=
SW620 M{\yW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjLdop2UUN3ME2xMlE{PTN2IN88US=> MmfYV2FPT0WU
HuP-T4 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rZPWlEPTB;MT6xPFM2QSEQvF2= MknlV2FPT0WU
A549 M37Zd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLHTWM2OD1zLkG5OVc3KM7:TR?= NX\wUWZWW0GQR1XS
Mewo NF\5dmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPZd3l2UUN3ME2xMlIxOjd4IN88US=> MnPHV2FPT0WU
ONS-76 M{C3XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3OyNGlEPTB;MT6yNlA1QSEQvF2= NFf5N2xUSU6JRWK=
SK-MEL-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTFwMkO0NVkh|ryP MYPTRW5ITVJ?
RCM-1 NH7TTnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIKwfpNKSzVyPUGuNlQxPDdizszN M4D0[HNCVkeHUh?=
H-EMC-SS NHzvXHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTFwMkm2NFgh|ryP NFTyR|hUSU6JRWK=
NCI-H2291 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTFwM{K1N|Yh|ryP NF\DdZZUSU6JRWK=
SW1463 Ml7QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXLTWM2OD1zLkOzO|IyKM7:TR?= NFfKUHRUSU6JRWK=
LS-411N NH;DNWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nyO2lEPTB;MT60NFUyPyEQvF2= NV;FZ4s1W0GQR1XS
BV-173 M2LjWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTFwNESwNVUh|ryP M1rs[XNCVkeHUh?=
LS-513 NXHUTWtuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rRRmlEPTB;MT60OVE6OiEQvF2= NHjFfXZUSU6JRWK=
LoVo M4i1VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTFwNE[zPVkh|ryP MnHlV2FPT0WU
HO-1-N-1 NFfOSXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LmPWlEPTB;MT61NVY{PCEQvF2= MXTTRW5ITVJ?
ML-2 NVPUZ5g1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTFwNUK4Olgh|ryP NWPzNXJlW0GQR1XS
NCI-H1437 M2KzOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnZeXhKSzVyPUGuOVUzPzVizszN NYrKOlB{W0GQR1XS
SW1116 M4HzN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknwTWM2OD1zLkW2N|k5KM7:TR?= M4j1THNCVkeHUh?=
A4-Fuk MmPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrKNI9DUUN3ME2xMlU4ODR3IN88US=> M4jG[3NCVkeHUh?=
HD-MY-Z NXvhUYE5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnRU4p4UUN3ME2xMlU4Ozd4IN88US=> MUDTRW5ITVJ?
SK-MEL-2 NG\n[XFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXv2SWhyUUN3ME2xMlU4PDV7IN88US=> NEXlZZhUSU6JRWK=
RT-112 NXzsTnBnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\4dotKSzVyPUGuOVg6PTJizszN NX\LWItIW0GQR1XS
COLO-829 MkjVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;id|JKSzVyPUGuOlIzOzJizszN NHvJSlVUSU6JRWK=
OVCAR-5 M{jTfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHOR25KSzVyPUGuO|c3QDdizszN NWrpenVxW0GQR1XS
NB69 M1TQdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWmyUJpOUUN3ME2xMlc5PDZ7IN88US=> NHv6T2VUSU6JRWK=
NCI-H292 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTFwOE[2PVkh|ryP Mn\iV2FPT0WU
LOXIMVI NICwbplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYOwVlZ2UUN3ME2xMlg6PDJ5IN88US=> MVXTRW5ITVJ?
BPH-1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDWZWJxUUN3ME2xMlg6PTlzIN88US=> NXHIXIVQW0GQR1XS
A375 Mo\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTFwOEm3NVQh|ryP MoDaV2FPT0WU
LCLC-97TM1 NWjae2FYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3oTWM2OD1zLkmyNlU3KM7:TR?= NXTaOIk2W0GQR1XS
RXF393 NXTGVYNET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDBTWM2OD1zLkm3PFg4KM7:TR?= MXrTRW5ITVJ?
HCC70 NV;NZWNuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV34[JVZUUN3ME2yMlAzPDJ4IN88US=> MVHTRW5ITVJ?
EM-2 MmDWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTJwMEexPVgh|ryP NU\TSVRlW0GQR1XS
MZ2-MEL MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;FbYxWUUN3ME2yMlEyOTJ5IN88US=> Mny5V2FPT0WU
HN M3rk[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTJwMU[yO|gh|ryP MYTTRW5ITVJ?
A2058 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILJcVZKSzVyPUKuNVkzPzlizszN MUHTRW5ITVJ?
NB7 MnzzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorTTWM2OD1{LkO0NFg3KM7:TR?= M3LIRnNCVkeHUh?=
DOK M1HYTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHRTWM2OD1{LkO1O|c{KM7:TR?= MX\TRW5ITVJ?
CAL-27 M2nPRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnHc|RKSzVyPUKuN|kzOzZizszN NF3QUIlUSU6JRWK=
BB65-RCC NHzJNplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnjTWM2OD1{LkSwOlc1KM7:TR?= Mny1V2FPT0WU
RD NFvjTFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4P6Z2lEPTB;Mj60OFczOyEQvF2= NID2blRUSU6JRWK=
KNS-62 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XKc2lEPTB;Mj61NVE3PCEQvF2= M3rre3NCVkeHUh?=
EW-13 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDuVGJKSzVyPUKuOVY{OzlizszN M3;rWHNCVkeHUh?=
DB NY\wXoVmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nCXmlEPTB;Mj61PFc5QCEQvF2= NGe3RWdUSU6JRWK=
HCC2218 NXTrT3VLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnZOXEzUUN3ME2yMlY1Pzd6IN88US=> NVHuNlFuW0GQR1XS
L-363 MnfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zwbGlEPTB;Mj63OFM4KM7:TR?= M2rqVHNCVkeHUh?=
CHL-1 NXrrSoZUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTJwOEC3PFUh|ryP NX3nb5JCW0GQR1XS
BFTC-905 M3TSc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfNbohuUUN3ME2yMlgzPTNizszN MmLJV2FPT0WU
HCE-T M330Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXxelFKSzVyPUKuPFMzPjRizszN MUnTRW5ITVJ?
COLO-792 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfPUnBKSzVyPUKuPFQxOjdizszN NF;CeYxUSU6JRWK=
LB2241-RCC NWDib|RkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPNNXNPUUN3ME2yMlg2QDl|IN88US=> Mnr6V2FPT0WU
CAL-39 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHYblRKSzVyPUKuPFk6QTlizszN MYjTRW5ITVJ?
T-24 NFvR[|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTJwOUGxNVIh|ryP NY\E[JRCW0GQR1XS
NCI-H727 NWf3RYRrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XvOmlEPTB;Mj65NVc6PiEQvF2= M2jNfHNCVkeHUh?=
Ca9-22 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXOycZBRUUN3ME2yMlk4OjV3IN88US=> MoPDV2FPT0WU
MIA-PaCa-2 NG\HbJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTNwMEC3PFEh|ryP NFPGVm5USU6JRWK=
HT-1080 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTNwMEG5PVch|ryP M3\xNnNCVkeHUh?=
D-423MG M2Swd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXhPG9KSzVyPUOuNFc4PTNizszN NVjDVopLW0GQR1XS
LAMA-84 M1TCTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDNTVZqUUN3ME2zMlE{PThizszN NGLqUG5USU6JRWK=
SW780 NG\6eoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\RWmlEPTB;Mz6xOFIzQSEQvF2= NXvwS2FTW0GQR1XS
KU-19-19 Mk[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjQXpFUUUN3ME2zMlE4ODN2IN88US=> NEHQOYpUSU6JRWK=
COLO-741 NYPP[ZJJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTNwMUi2O|Mh|ryP NU\nOFRWW0GQR1XS
HSC-3 Mn7lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\BO2lEPTB;Mz6yN|E2OSEQvF2= NVjGS|F2W0GQR1XS
SN12C M{LyXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HxPWlEPTB;Mz6yOFcxOSEQvF2= M1LZSnNCVkeHUh?=
786-0 NHvpZ4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTNwMkeyOFMh|ryP MkPWV2FPT0WU
GAK M1TFdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTNwM{K1OlEh|ryP M4\tTHNCVkeHUh?=
PANC-03-27 NVnzcVJJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTLb|FMUUN3ME2zMlM2ODR3IN88US=> NIjuSYZUSU6JRWK=
CTB-1 NIXxXnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnhV3JKSzVyPUOuOFcxPDdizszN NWGyNVg1W0GQR1XS
A427 NIfkWYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnZU49lUUN3ME2zMlU6PTV4IN88US=> NEDoWGNUSU6JRWK=
EGI-1 M2OzOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LwT2lEPTB;Mz62NFU5OyEQvF2= MWPTRW5ITVJ?
U-2-OS MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTNwNkeyOVYh|ryP M2DKTHNCVkeHUh?=
NCI-SNU-5 Ml75S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrQV4l{UUN3ME2zMlY4PzNizszN NVvxSFV4W0GQR1XS
SK-LU-1 NHPrTo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NISxdXRKSzVyPUOuOlg4QThizszN NHnRSmZUSU6JRWK=
697 MmPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\iUItKSzVyPUOuOlk3ODNizszN MXXTRW5ITVJ?
HPAF-II MoLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTNwN{W0PUDPxE1? NW\NeotXW0GQR1XS
NCI-H2087 MlXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3DTWM2OD1|Lki0OlczKM7:TR?= NYPUU3FtW0GQR1XS
SK-MEL-3 Mo\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXqVpZKSzVyPUOuPFUyPTRizszN M2myW3NCVkeHUh?=
CGTH-W-1 NVjYOHIzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3E[3hKSzVyPUOuPFU4OjVizszN M2\PR3NCVkeHUh?=
8505C MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rpUWlEPTB;Mz65NFA4QCEQvF2= MX;TRW5ITVJ?
GAMG MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTRwMEKzO|ch|ryP MV7TRW5ITVJ?
SW626 M4T0Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXr0PYJWUUN3ME20MlA1PDhizszN NVXk[FV7W0GQR1XS
CAL-62 NVz4eIRvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTwTWM2OD12LkC3OFMh|ryP NF;VNohUSU6JRWK=
MHH-PREB-1 NWXDS|BqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTRwMUKxNVEh|ryP NULsdJJIW0GQR1XS
RPMI-7951 NIj5SIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPwdFdZUUN3ME20MlI2PTh7IN88US=> M4e2UnNCVkeHUh?=
HOP-92 M3y4Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnv5TWM2OD12LkK1Olch|ryP MknIV2FPT0WU
MDA-MB-231 MoH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3KTWM2OD12LkK5NlI{KM7:TR?= MnnhV2FPT0WU
LAN-6 MlXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVznd4ZpUUN3ME20MlMyPjN5IN88US=> MYTTRW5ITVJ?
ALL-PO M3K0O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DTeWlEPTB;ND6zOlE2PiEQvF2= NFPrU5BUSU6JRWK=
HH M{jtVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\0c21KSzVyPUSuOFE2QTdizszN MULTRW5ITVJ?
IGROV-1 Mkj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTRwNEWxO|Eh|ryP Ml7mV2FPT0WU
NCI-H358 NVjMdY1{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofoTWM2OD12LkS1N|g2KM7:TR?= NVTmN4JEW0GQR1XS
NB5 M{DmVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUf3U3R7UUN3ME20MlYxOzZ7IN88US=> MVrTRW5ITVJ?
NCI-H747 NU\oOItQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjGfZNQUUN3ME20MlY5QDB5IN88US=> NFXLS41USU6JRWK=
NH-12 NXj5NY5nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTFUJZ7UUN3ME20MlcyPjJ3IN88US=> NXvrfm46W0GQR1XS
LB1047-RCC M3nEUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTRwN{O4NVUh|ryP M{\Ke3NCVkeHUh?=
EFO-27 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1K4b2lEPTB;ND63PFY3PyEQvF2= NWTmToNEW0GQR1XS
EPLC-272H Mm\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\IVlZKSzVyPUSuPVk3PjlizszN M2PCcnNCVkeHUh?=
CAL-54 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HicmlEPTB;NT6wNlY6PSEQvF2= NIDwPHNUSU6JRWK=
H4 M2C3SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\vSoxmUUN3ME21MlA1OjV3IN88US=> M1Ps[nNCVkeHUh?=
MOLT-13 NWjvXYtvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTVwME[3O|Yh|ryP M1v0TnNCVkeHUh?=
CAL-33 NF7VO2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEToWHZKSzVyPUWuNVI{OTdizszN MnrLV2FPT0WU
23132-87 NETMTmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\lTWM2OD13LkG2PFczKM7:TR?= Mm\VV2FPT0WU
UM-UC-3 MoLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTVwMUiwOFch|ryP NHfib2dUSU6JRWK=
HuH-7 NEK4NI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTVwMkexOFch|ryP NWrHXo83W0GQR1XS
BCPAP M{HCbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fJdmlEPTB;NT6zNlk3QSEQvF2= NVHvV|F7W0GQR1XS
AsPC-1 NG\L[3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDHXWVKSzVyPUWuN|Y4PjNizszN MWTTRW5ITVJ?
NCI-H1155 NUCwWnRkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPXfmZKSzVyPUWuOFAxPTFizszN M1X1PXNCVkeHUh?=
GT3TKB MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHiOpdpUUN3ME21MlQ3PTl6IN88US=> NXnFVYJWW0GQR1XS
HCC2998 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXG3VFdKUUN3ME21MlQ6OTB7IN88US=> NIHoPGhUSU6JRWK=
NUGC-3 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLU[VZKSzVyPUWuOFk{ODJizszN MX;TRW5ITVJ?
Hs-578-T MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{T5d2lEPTB;NT61N|c6PCEQvF2= NIDGenhUSU6JRWK=
FADU MoHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWqyXWdyUUN3ME21MlU2PzJ4IN88US=> MnzuV2FPT0WU
NBsusSR Mmr3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmi1TWM2OD13LkW3NVU2KM7:TR?= M3;WVnNCVkeHUh?=
ME-180 NW\zUmFnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTVwNUiwPVIh|ryP NYDT[5RnW0GQR1XS
SW1710 M1PBS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVy0Ooc5UUN3ME21MlYyPjV2IN88US=> MnP3V2FPT0WU
HuP-T3 Mor0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrPTWM2OD13Lk[yNFI6KM7:TR?= M{fwRXNCVkeHUh?=
HOS M1:4OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlX2TWM2OD13Lk[yPVI{KM7:TR?= NEHybVFUSU6JRWK=
PA-1 NYK3TZl2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLZVZVKSzVyPUWuOlQzPjVizszN NIqyc25USU6JRWK=
LU-99A M3fQW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37Ib2lEPTB;NT62OlQ2OSEQvF2= NF;BenVUSU6JRWK=
RS4-11 NWDST5l1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PMVGlEPTB;NT62Olc4PSEQvF2= NVuydpJ1W0GQR1XS
TE-8 NEDNfW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTVwNki1N|ch|ryP NIDOeY9USU6JRWK=
RERF-LC-MS M3nBfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXFTWM2OD13Lk[4PFA{KM7:TR?= NFPMW2tUSU6JRWK=
MEL-JUSO MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHETWM2OD13LkezO|gh|ryP MYHTRW5ITVJ?
SK-MES-1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTVwOEO1Nlgh|ryP M4Lj[XNCVkeHUh?=
D-263MG NGfzclFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XZcmlEPTB;NT64PFM2OSEQvF2= NGnjeJJUSU6JRWK=
NB10 MnjWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\M[mlEPTB;NT64PVQ3KM7:TR?= Mly5V2FPT0WU
SK-HEP-1 NY[2VW5IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NID5PFhKSzVyPUWuPVM1PzFizszN M4\NfHNCVkeHUh?=
HT-29 NY[2WHVpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHqW2hnUUN3ME21Mlk5OTF6IN88US=> NF:1ZW5USU6JRWK=
KYSE-140 M4Pjc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTZwMEKxPFIh|ryP NX[2ZodCW0GQR1XS
NCI-H1666 NXvqdZBET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWL3OnJ7UUN3ME22MlA5PDZzIN88US=> NYnYTVFDW0GQR1XS
NCI-H1304 MnvZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzLWI1PUUN3ME22MlE6QTRizszN MUTTRW5ITVJ?
RPMI-8866 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7M[oM6UUN3ME22MlIyOzF|IN88US=> Ml;HV2FPT0WU
MV-4-11 NEHVUGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXOelR3UUN3ME22MlI{OTl7IN88US=> M1G1eHNCVkeHUh?=
A431 NGrCTJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfkc5BKSzVyPU[uNlQzQTZizszN NV3ieWtWW0GQR1XS
PANC-10-05 Ml\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTZwMkizOlMh|ryP M1POTHNCVkeHUh?=
TK10 NV;lRotrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXKdGZDUUN3ME22MlMzPjB2IN88US=> Mn;NV2FPT0WU
NCI-H1975 MmrnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3:2VGlEPTB;Nj60O|IyPSEQvF2= M2jIZXNCVkeHUh?=
A172 NHHMU3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjWXoVKSzVyPU[uOFkyPzZizszN Mk\FV2FPT0WU
D-566MG NGDKSY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\sTWM2OD14LkW0N|A{KM7:TR?= NHm2fGdUSU6JRWK=
NCI-H2122 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;MTG9KSzVyPU[uOlE2OjhizszN NGX1cJFUSU6JRWK=
COR-L105 NGH1TZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHDTWM2OD14Lk[1Nlc2KM7:TR?= NU[5VpFPW0GQR1XS
AN3-CA NIHRVIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHVUoJKSzVyPU[uOlg3PDFizszN MmP1V2FPT0WU
Calu-6 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\PXo1KSzVyPU[uO|k3QThizszN NEXEZmlUSU6JRWK=
HCT-116 NInpcFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnVVFZ4UUN3ME22MlgyOjZ2IN88US=> MWrTRW5ITVJ?
MHH-NB-11 NGLHe4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\MbmFHUUN3ME22Mlg2ODB{IN88US=> NF3HXpRUSU6JRWK=
MFE-280 NV74eHhYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETY[VVKSzVyPU[uPFU6QDNizszN MVvTRW5ITVJ?
SW1088 NGS0e2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTZwOUG5NVMh|ryP M3HBZ3NCVkeHUh?=
SW48 M2\GXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjjb2hKSzVyPU[uPVQ2OSEQvF2= NY[wVoNSW0GQR1XS
HuCCT1 M3faZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrpc3RpUUN3ME23MlAyODN5IN88US=> M3;KPHNCVkeHUh?=
ACHN MorHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH[zUFVKSzVyPUeuNFI6PDNizszN NX3ve2dJW0GQR1XS
8305C NE\6OVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXR[49KSzVyPUeuNFk6QTVizszN MkKxV2FPT0WU
DoTc2-4510 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfOVJVKSzVyPUeuNVIyPSEQvF2= M2\tcXNCVkeHUh?=
COR-L23 M16zO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXPTWM2OD15LkK0OFIh|ryP Mni2V2FPT0WU
SK-MEL-30 Mn36S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTdwMkWwPFMh|ryP MXvTRW5ITVJ?
BE-13 MnvCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTdwM{O4N|Qh|ryP NX64UHM4W0GQR1XS
GR-ST NFfoe2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DVSGlEPTB;Nz60NFE4PCEQvF2= MWDTRW5ITVJ?
LU-135 NULTXIg3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoG0TWM2OD15LkW1PVM6KM7:TR?= NXLsbHlNW0GQR1XS
U-266 NHfZdGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTdwNU[yPFYh|ryP MVvTRW5ITVJ?
NCI-H1355 MofjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTdwNUi2N|Uh|ryP NGXN[2tUSU6JRWK=
NB14 MkfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jRSGlEPTB;Nz62OlY1OiEQvF2= MXjTRW5ITVJ?
SCC-25 NYPUeoJKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnOwTWM2OD15LkewPUDPxE1? NHHBVGVUSU6JRWK=
COLO-678 M2\zcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTdwN{GwO|Yh|ryP NFX0NndUSU6JRWK=
TGBC1TKB M1HiZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;hN2lKSzVyPUeuPFk{QThizszN M33sN3NCVkeHUh?=
IST-MEL1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\1[VMxUUN3ME24MlAxPDB4IN88US=> M{m2TnNCVkeHUh?=
ECC10 NWfYclJpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzHTWM2OD16LkCzN|k2KM7:TR?= MX3TRW5ITVJ?
EW-16 NG\JS|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRThwMEi0OFUh|ryP M4nLcnNCVkeHUh?=
DOHH-2 Ml[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjkS4w4UUN3ME24MlIxODl3IN88US=> M2HOeHNCVkeHUh?=
NCI-H1581 M3vtOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEn3NItKSzVyPUiuNlY{OjNizszN M4HGZXNCVkeHUh?=
TE-5 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUj6T5F4UUN3ME24MlQzPDJ7IN88US=> NVTXXY5pW0GQR1XS
CAKI-1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLRTWM2OD16LkW3NlIzKM7:TR?= M1Hm[HNCVkeHUh?=
A673 M1;keWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHhTWM2OD16Lk[zNlAzKM7:TR?= M3;KbXNCVkeHUh?=
CAL-12T NHXjdJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULacJhGUUN3ME24MlY2PzV|IN88US=> MUPTRW5ITVJ?
DBTRG-05MG MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRThwN{S4OVkh|ryP NWKyWYFDW0GQR1XS
SK-N-FI NEHEeWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEn4WZFKSzVyPUiuPFE{PzlizszN NU\qV3pUW0GQR1XS
K-562 MnvIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LXfGlEPTB;OD64N|k2PyEQvF2= NVPyNHJkW0GQR1XS
SBC-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRThwOE[2OFUh|ryP NEfoUI1USU6JRWK=
ES4 NF\3U3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnPTWM2OD16Lki2PFg1KM7:TR?= MVTTRW5ITVJ?
MS-1 NX7HdJpET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRThwOEe1NVch|ryP NWXxOmxnW0GQR1XS
RKO Mk\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnhTWM2OD16Lki5NFU4KM7:TR?= NYDrcWM4W0GQR1XS
NCI-H1693 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\2SFFvUUN3ME24MlkzOTdizszN NWjT[3p{W0GQR1XS
SW954 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXzUnF6UUN3ME24Mlk3QTd6IN88US=> MoS5V2FPT0WU
SK-UT-1 Mn;FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;rcXJKSzVyPUiuPVc3QDNizszN NYHiOJd7W0GQR1XS
T98G NXvpWXlOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\rUXdpUUN3ME24Mlk6QDR4IN88US=> NH63T49USU6JRWK=
NCI-H2126 NYPqVFh5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfJcYZIUUN3ME25MlAxQDJ4IN88US=> MYLTRW5ITVJ?
TE-12 NGnLO3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTlwMEOzOlch|ryP NH21fWhUSU6JRWK=
DK-MG MoPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXjSY1KSzVyPUmuNlEyQTFizszN MVrTRW5ITVJ?
MEG-01 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1H1S2lEPTB;OT6yOFk{OSEQvF2= MVrTRW5ITVJ?
HCC1937 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2X2S2lEPTB;OT6yPVA6OSEQvF2= NXLrVHo2W0GQR1XS
MKN45 NFexeXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfNXmJKSzVyPUmuOFUxPjVizszN MkXpV2FPT0WU
NCI-H1792 NILGSHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHVTWM2OD17LkS1NlE6KM7:TR?= NUHIWFg1W0GQR1XS
SW1417 MmnNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{Dn[2lEPTB;OT61Olg{PyEQvF2= MXzTRW5ITVJ?
639-V NH3WPYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmr1TWM2OD17Lk[0N|g5KM7:TR?= Mn\0V2FPT0WU
P30-OHK M1SyOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnWzTWM2OD17Lk[1N|E3KM7:TR?= Ml7DV2FPT0WU
YKG-1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTlwN{WwN|Mh|ryP M3rTPHNCVkeHUh?=
KGN M2\hXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTlwOEO3PVUh|ryP MULTRW5ITVJ?
MSTO-211H NGDUOZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV[2XpF2UUN3ME25Mlk2PTJ7IN88US=> Mm\OV2FPT0WU
NCI-H1573 NFj5b|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rZUGlEPTB;MUCuNVU4PCEQvF2= NFjJXYpUSU6JRWK=
NCI-H720 M4LzfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3Poc2lEPTB;MUCuNVk5QSEQvF2= M{PTXXNCVkeHUh?=
KARPAS-45 M1TxUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nQV2lEPTB;MUCuNlc6PSEQvF2= Mn3sV2FPT0WU
MDA-MB-175-VII MljyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTFyLkS4JO69VQ>? NXTHUVlNW0GQR1XS
SK-NEP-1 NHSxOXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnOzTWM2OD1zMD60PVgyKM7:TR?= M4XaVXNCVkeHUh?=
MKN28 Mn\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTFyLkWxPEDPxE1? NX[yelhmW0GQR1XS
KYSE-520 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTFyLkWyJO69VQ>? NGTiW5BUSU6JRWK=
KE-37 NX3pZ|FRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPyTWM2OD1zMD61NlczKM7:TR?= MnPVV2FPT0WU
VA-ES-BJ MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTFyLkW2O{DPxE1? M4HETHNCVkeHUh?=
CCRF-CEM MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPYfnE4UUN3ME2xNE42Pjh2IN88US=> MU\TRW5ITVJ?
GMS-10 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7ieFJKSzVyPUGwMlYxQTRizszN NF[4d41USU6JRWK=
NCI-H1623 NHPiUmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYW3XYM2UUN3ME2xNE43Ozd7IN88US=> MVzTRW5ITVJ?
NEC8 NVrHWW9sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TRcmlEPTB;MUCuO|c4OyEQvF2= M3fXdHNCVkeHUh?=
MOLT-16 M1vMd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrS[JBKSzVyPUGwMlgyOTNizszN NXnzc4ZlW0GQR1XS
DJM-1 NWHFfo46T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfoUG5KSzVyPUGxMlA{PzlizszN MVXTRW5ITVJ?
U251 NHLDWW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrJdGFnUUN3ME2xNU4xPDJizszN MmfPV2FPT0WU
SBC-5 NXSzTGdtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfURpFRUUN3ME2xNU4yPDZ5IN88US=> NHS3doZUSU6JRWK=
SW756 M4T3R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDHTVlzUUN3ME2xNU4zOTV2IN88US=> NHX1d|NUSU6JRWK=
KS-1 NYHtS|htT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHaTnpRUUN3ME2xNU4zPjF7IN88US=> MXfTRW5ITVJ?
SF295 M3TDUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTjWYFKSzVyPUGxMlMyODRizszN M3TsN3NCVkeHUh?=
YH-13 NGntOotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTFzLkOyOlch|ryP MmjsV2FPT0WU
SW837 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\LcVhrUUN3ME2xNU4{PTB4IN88US=> NWHOWWhNW0GQR1XS
KYSE-450 M2PuXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDhO5NSUUN3ME2xNU41ODV5IN88US=> MmS3V2FPT0WU
KYSE-180 NEG5SWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofDTWM2OD1zMT60PFIh|ryP NInIe2ZUSU6JRWK=
S-117 NUDVNHczT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTFzLkS4PVYh|ryP MmTQV2FPT0WU
KOSC-2 NV75UIVtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXi4[ZZWUUN3ME2xNU43OjJ{IN88US=> MnvZV2FPT0WU
KYSE-270 M17oPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4npSWlEPTB;MUGuPFc1PSEQvF2= NF22U4RUSU6JRWK=
D-336MG M2q2NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfCSYxKSzVyPUGxMlkxPzVizszN NF:3[oxUSU6JRWK=
KALS-1 M3;UXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrvWmRxUUN3ME2xNk4xODF4IN88US=> NV76[G83W0GQR1XS
LB373-MEL-D Ml7WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYj1dJBwUUN3ME2xNk4xPTN|IN88US=> NYjYNJlmW0GQR1XS
HLE MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHuyO2NKSzVyPUGyMlA2QDVizszN NXPGZ45YW0GQR1XS
SJSA-1 M3zRT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTF{LkC3N|Uh|ryP MmGzV2FPT0WU
SW1990 NFyxbZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPublhKSzVyPUGyMlA6OTFizszN NWPaO5B7W0GQR1XS
NOS-1 M1PQSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfJUY9bUUN3ME2xNk4yOzV{IN88US=> M{\hRXNCVkeHUh?=
GI-ME-N NHfmSIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrMXWRKSzVyPUGyMlIyPjNizszN NILGXWxUSU6JRWK=
NCI-H1703 NUT1cJV2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHkWXBKSzVyPUGyMlI3OTZizszN MYXTRW5ITVJ?
ES7 M3rRSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\IUWlEPTB;MUKuNlczPCEQvF2= M{\ORnNCVkeHUh?=
KYSE-510 NVK3VHlKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rFeWlEPTB;MUKuOVA4QSEQvF2= M3;vfXNCVkeHUh?=
BHY MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3roWWlEPTB;MUKuOVMxPyEQvF2= NV\JZoJrW0GQR1XS
TCCSUP MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF[wPYRKSzVyPUGyMlU4PTdizszN NFvxc3VUSU6JRWK=
HSC-2 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfzbYpKSzVyPUGyMlU6QTZizszN MUjTRW5ITVJ?
BEN NI\4R4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnLSlFHUUN3ME2xNk43OTR|IN88US=> M1u0VHNCVkeHUh?=
769-P NGXDPGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTFTWM2OD1zMj63PVI1KM7:TR?= MXvTRW5ITVJ?
HT NWrT[oo4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\RTWM2OD1zMj64N|Q3KM7:TR?= M2fOfnNCVkeHUh?=
LXF-289 M4PiUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;mfo5KSzVyPUGyMlk2OzFizszN M3S2RnNCVkeHUh?=
OVCAR-3 M4jz[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTQVnBKSzVyPUGyMlk2PjdizszN M1v0NHNCVkeHUh?=
ATN-1 NEfOOFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTF|LkCxPFQh|ryP NHezSHlUSU6JRWK=
8-MG-BA NG\ifZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTF|LkC0OVUh|ryP Mlj5V2FPT0WU
SW13 NFfpU3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWWxNGRTUUN3ME2xN{4yOTZ3IN88US=> Mn\rV2FPT0WU
NCI-H1092 NF\ySZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHEOVZ7UUN3ME2xN{4yPjJizszN M1OzNnNCVkeHUh?=
OAW-42 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\jTWM2OD1zMz6xPVM4KM7:TR?= MkTkV2FPT0WU
NCI-H2452 MnP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXST|ZKSzVyPUGzMlIyPzVizszN M4e3R3NCVkeHUh?=
CAPAN-1 M3TZeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV:1N5dnUUN3ME2xN{42PTF2IN88US=> NVnaPVlIW0GQR1XS
NCI-H2009 MkLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTF|LkW5NVkh|ryP MojxV2FPT0WU
SF268 M3HofGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfq[pFKSzVyPUGzMlY{OjZizszN M{CxTXNCVkeHUh?=
GCIY Ml7kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnf3TWM2OD1zMz62PVI4KM7:TR?= M1fSOnNCVkeHUh?=
OS-RC-2 NX7sb|RmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTF|Lkm1NFEh|ryP Ml22V2FPT0WU
GCT M2PwWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTF|Lkm2PVch|ryP NXnzemdpW0GQR1XS
NB17 M1\hVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TY[WlEPTB;MUSuNFg2KM7:TR?= M3fSeHNCVkeHUh?=
NCI-H2030 M{Xn[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTkXG8xUUN3ME2xOE4yPDZ3IN88US=> MoHUV2FPT0WU
HC-1 MnzKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzoV45FUUN3ME2xOE4zODh5IN88US=> NUHy[FlGW0GQR1XS
QIMR-WIL M2TwcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTF2LkO0NVIh|ryP M37kVnNCVkeHUh?=
Capan-2 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mly5TWM2OD1zND6zO|E1KM7:TR?= NIPKd3ZUSU6JRWK=
BALL-1 M1Gyb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXmXVBKSzVyPUG0MlQ3PjVizszN MVnTRW5ITVJ?
LS-1034 NX3MUHdxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTF2Lk[xOVIh|ryP NILnSZhUSU6JRWK=
U-118-MG NXnMdpRwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEj1c4ZKSzVyPUG0MlY{OSEQvF2= MWPTRW5ITVJ?
NCI-H630 M3XoPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTF2Lk[1Olgh|ryP NXTSNYM3W0GQR1XS
OVCAR-8 Mn;uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrQTWM2OD1zND63NlAyKM7:TR?= MmDJV2FPT0WU
NCI-H2347 Ml7aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTF2LkiyN{DPxE1? NYK2S5AxW0GQR1XS
BT-549 M2jKNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX21dG1bUUN3ME2xOE45Ojh2IN88US=> M2HLbXNCVkeHUh?=
LB831-BLC NWPmb2NxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnKSFJKSzVyPUG0Mlg6OzRizszN MXPTRW5ITVJ?
NCI-H661 M3vKRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\VTWM2OD1zND65OVkh|ryP MnnLV2FPT0WU
MKN7 NGThflRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTF3LkCwPVMh|ryP M2\ZbHNCVkeHUh?=
U-87-MG Mo\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmS2TWM2OD1zNT6wPFk4KM7:TR?= MlTtV2FPT0WU
OVCAR-4 NHzrVmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3L6WWlEPTB;MUWuNVQzPCEQvF2= NIr6V5pUSU6JRWK=
OE33 NGTndoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnwTWM2OD1zNT6xO|EyKM7:TR?= M{XiXnNCVkeHUh?=
EC-GI-10 M3HqN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nUOWlEPTB;MUWuNlM2PyEQvF2= MVfTRW5ITVJ?
AM-38 MoXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTF3LkK3NVch|ryP M4XSfXNCVkeHUh?=
NCI-H1563 M3rSUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vndGlEPTB;MUWuN|Q6KM7:TR?= NIrOZ3pUSU6JRWK=
SCC-4 M4jOdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rBR2lEPTB;MUWuOFExOyEQvF2= NWrCc3R{W0GQR1XS
Detroit562 M3n6SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTF3LkS1OFch|ryP MlHBV2FPT0WU
PC-14 M3vjbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTF3LkS4OlYh|ryP MkTHV2FPT0WU
ES3 MnLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjHPIV5UUN3ME2xOU42OzZizszN MYfTRW5ITVJ?
OCI-AML2 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTF3Lke2NVQh|ryP MV\TRW5ITVJ?
LU-134-A MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1qwU2lEPTB;MUWuPVAyQCEQvF2= MknrV2FPT0WU
SAS MmjFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojCTWM2OD1zNT65N|c{KM7:TR?= M362T3NCVkeHUh?=
TGBC11TKB MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTF3Lkm0NVQh|ryP NELWXYFUSU6JRWK=
HOP-62 NYnnNWVxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHOO|BjUUN3ME2xOU46PTl5IN88US=> MXTTRW5ITVJ?
G-401 NXPDVpVtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTF3Lkm2OFkh|ryP MX;TRW5ITVJ?
NCI-H28 MlHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojtTWM2OD1zNj6wPFU3KM7:TR?= NXHVcVlTW0GQR1XS
A204 M{PqO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvUe5c6UUN3ME2xOk4zODB4IN88US=> NVm1Ooo{W0GQR1XS
NCI-H1299 NFPz[4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrN[YZsUUN3ME2xOk4zOjlzIN88US=> MmrMV2FPT0WU
VMRC-RCZ M4Lacmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3nb4ZDUUN3ME2xOk4zPTl{IN88US=> NHTRc25USU6JRWK=
BxPC-3 M3P0Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWT4XVlrUUN3ME2xOk4zQDV4IN88US=> NX\jWFE4W0GQR1XS
NCI-H2228 M4XTN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVO0TpZxUUN3ME2xOk42OTV6IN88US=> NIjWWVlUSU6JRWK=
NCI-H23 NInMWlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTF4Lk[wO|gh|ryP NVnFPVF6W0GQR1XS
NKM-1 NVyxUXZCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrNTWM2OD1zNz6wNVg6KM7:TR?= NXjvcmVFW0GQR1XS
KYSE-70 NUjjXpJlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHX1XYpKSzVyPUG3MlI5QSEQvF2= NILVcYRUSU6JRWK=
BB49-HNC NHq0PWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;yVmlEPTB;MUeuOVY5PiEQvF2= M4i3RnNCVkeHUh?=
SCC-15 M{PBNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzMU|JKSzVyPUG3Mlg1PzNizszN NF;HenNUSU6JRWK=
D-247MG NVnUSZF5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTF5LkmyOFch|ryP NULMcZo3W0GQR1XS
BB30-HNC MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTF6LkCzNVgh|ryP M3jJfXNCVkeHUh?=
CAL-85-1 MkfuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvYTWM2OD1zOD6xPFA6KM7:TR?= NYLBPGt7W0GQR1XS
HT-3 M2flfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjzNXdKSzVyPUG4MlM6PzdizszN Mln2V2FPT0WU
KYSE-410 M{TkTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17kcGlEPTB;MUiuOFU4PyEQvF2= M{LaeXNCVkeHUh?=
SW982 NXSyS3lwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXFcVJ{UUN3ME2xPE42PjR7IN88US=> NHnnSWNUSU6JRWK=
SW962 NUfOVopCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXKUZZKSzVyPUG4MlU4ODJizszN NYq1c5ZJW0GQR1XS
Ramos-2G6-4C10 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;NSppNUUN3ME2xPE42QTJ5IN88US=> NEf4VGZUSU6JRWK=
OC-314 M{HxRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fmU2lEPTB;MUiuO|M5PCEQvF2= NGTTTGVUSU6JRWK=
LS-123 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHH0NIdKSzVyPUG4Mlc6ODFizszN Mon4V2FPT0WU
D-502MG MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTF6LkixN|kh|ryP MkPoV2FPT0WU
RO82-W-1 NUW2bFBiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;mWVlKSzVyPUG4MlgzQDhizszN MYHTRW5ITVJ?
HuO9 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LSSWlEPTB;MUmuNVM4QSEQvF2= M1XFcXNCVkeHUh?=
ETK-1 M4iw[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTVTWM2OD1zOT6xPFI4KM7:TR?= Mn3qV2FPT0WU
SNU-387 M4\E[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\nSGlEPTB;MUmuNVg5QSEQvF2= M4rMeXNCVkeHUh?=
SW1573 MnrES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHDVoNjUUN3ME2xPU4yQTZ7IN88US=> MXHTRW5ITVJ?
NTERA-S-cl-D1 MmP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTF7LkKwNFch|ryP MkjhV2FPT0WU
SF126 M{HVZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTF7LkO1NFIh|ryP MmK3V2FPT0WU
Calu-3 M3zhTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\xZmlEPTB;MUmuOFI{PyEQvF2= MYPTRW5ITVJ?
NCI-H1048 MoHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTJyLkOyOlYh|ryP M{DaUHNCVkeHUh?=
NCI-H226 M2\BZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXizTWpnUUN3ME2yNE41Ozl7IN88US=> M{\Je3NCVkeHUh?=
FTC-133 NXHne|lmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrMZ4pKSzVyPUKwMlQ4ODNizszN MVfTRW5ITVJ?
SF539 NFTJU5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;OWWRKSzVyPUKwMlUyPzJizszN M4r0enNCVkeHUh?=
TE-6 NXi3Z5JXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfzWI9KSzVyPUKwMlgxPjdizszN Ml:yV2FPT0WU
UMC-11 NEG0e3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3ncYRVUUN3ME2yNE46OTZ2IN88US=> NXHZWm56W0GQR1XS
Becker NYHDSmdOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTNTmtTUUN3ME2yNU4yOTF6IN88US=> NY[z[YhlW0GQR1XS
KP-4 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVK4cJhmUUN3ME2yNU4yOTl4IN88US=> M4nVUHNCVkeHUh?=
ChaGo-K-1 NYnzelZZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTJzLkO2Nlch|ryP NIrNNG1USU6JRWK=
CFPAC-1 M1fWWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7BfG5NUUN3ME2yNU4{QDV6IN88US=> MXHTRW5ITVJ?
A498 MmLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDuVYtKSzVyPUKxMlU{OTJizszN NGTndGlUSU6JRWK=
NCI-H1755 NI[zcpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTJzLk[3OFEh|ryP NFnGXXJUSU6JRWK=
TI-73 NV;wRmE2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37hfmlEPTB;MkKuN|I5KM7:TR?= NVrIb|ZWW0GQR1XS
NCI-H441 NXiwOJVsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTJ{LkW2PFkh|ryP NHPLOY5USU6JRWK=
CaR-1 Mkm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nKTWlEPTB;MkOuNFIyOyEQvF2= MkPXV2FPT0WU
HCC1806 NWO3O5VJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLjS25RUUN3ME2yN{4xPTh|IN88US=> NUnhWJZoW0GQR1XS
SNU-449 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HweGlEPTB;MkOuN|I6KM7:TR?= MWDTRW5ITVJ?
EKVX M3jNS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlW2TWM2OD1{Mz6zPVA6KM7:TR?= NXTMcpNOW0GQR1XS
DMS-114 NV3aT5VVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTJ|LkW3OlUh|ryP NX:3U|JXW0GQR1XS
A704 MnLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrTTWM2OD1{Mz62NVA{KM7:TR?= MX7TRW5ITVJ?
LC-2-ad NXPjbIJyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTJ|Lk[xOFch|ryP NVfLWYp4W0GQR1XS
VM-CUB-1 NV;wfY41T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnH3TWM2OD1{Mz63N|QyKM7:TR?= MVzTRW5ITVJ?
PC-3 NGHQNlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTJ2LkC1NlYh|ryP M2\NWXNCVkeHUh?=
HEL NFzFXo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PrPGlEPTB;MkSuNFg3PSEQvF2= M1jRV3NCVkeHUh?=
ABC-1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PFfGlEPTB;MkSuNlczQSEQvF2= NGXHcmZUSU6JRWK=
COLO-680N MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn2xTWM2OD1{ND60O|Y1KM7:TR?= NGH4T4VUSU6JRWK=
MZ1-PC MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTJ2Lk[4O{DPxE1? MlqzV2FPT0WU
NCI-H69 MlXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoG1TWM2OD1{ND63N|U1KM7:TR?= MUXTRW5ITVJ?
TE-1 M{P1[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfhfYUyUUN3ME2yOU4xPDl7IN88US=> NXfRb|J3W0GQR1XS
EW-3 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHjbnNKSzVyPUK1MlEyOyEQvF2= M3nBUHNCVkeHUh?=
PANC-08-13 M1rxbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrkS4hKSzVyPUK1MlgyODNizszN M4H0XnNCVkeHUh?=
NMC-G1 MlPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLDZ4FxUUN3ME2yOk4xODh6IN88US=> NGTHTFlUSU6JRWK=
BT-20 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfZTWM2OD1{Nj60OVQ{KM7:TR?= M13vSnNCVkeHUh?=
TGBC24TKB NWGzbZpyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTJ4LkezN|Eh|ryP M{jHNXNCVkeHUh?=
TE-11 Ml\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnL3TWM2OD1{Nj65PFk2KM7:TR?= NI\Jc21USU6JRWK=
ESS-1 M{DpcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfPS49KSzVyPUK3MlMzOTZizszN MX3TRW5ITVJ?
JVM-3 M4DMZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoG1TWM2OD1{Nz62OFc2KM7:TR?= MkXQV2FPT0WU
C3A MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfZTWM2OD1{Nz64OFk3KM7:TR?= NUjGOJJkW0GQR1XS
MDA-MB-157 M{i1TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4i5fmlEPTB;MkeuPFc2OyEQvF2= NVjCXJJ{W0GQR1XS
KLE M4rpU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTJ6LkGwOVgh|ryP NEHEXYRUSU6JRWK=
ES1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTJ6LkG4N|gh|ryP M1fmc3NCVkeHUh?=
CAL-120 M{TxZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLiTGI3UUN3ME2yPE4{QTl7IN88US=> MXzTRW5ITVJ?
NCI-N87 M1rJTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjnTWM2OD1{OD61NVA2KM7:TR?= Mn;NV2FPT0WU
RPMI-8226 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzxRlFKSzVyPUK5MlE5PDNizszN MYrTRW5ITVJ?
COR-L88 M1q3T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XuSGlEPTB;MkmuNlQyQSEQvF2= NVrBOWJ3W0GQR1XS
UACC-893 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTJ7LkOxN|ch|ryP NEnzbXBUSU6JRWK=
C8166 MmK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XVN2lEPTB;MkmuPVk6PiEQvF2= NFLFWHBUSU6JRWK=
J82 NXXyO3NKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3y3VGlEPTB;M{CuPFE1PyEQvF2= NG\2XZFUSU6JRWK=
PFSK-1 M3raeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTNzLkC2OVkh|ryP MWXTRW5ITVJ?
COLO-684 NWTzfXhJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHeySHZKSzVyPUOxMlQ{PzRizszN MV;TRW5ITVJ?
CAL-72 MnL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE[z[oNKSzVyPUOxMlU4OjlizszN MkPlV2FPT0WU
SNB75 Ml;0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTNzLki5O{DPxE1? NWfRXpg2W0GQR1XS
MDA-MB-415 MkO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vF[WlEPTB;M{GuPVc3OiEQvF2= M2fHNXNCVkeHUh?=
SiHa NVLYT3RDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4f0e2lEPTB;M{KuOFcyOSEQvF2= M{W2[XNCVkeHUh?=
NCI-H1648 NICxZndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHX6UnBKSzVyPUOyMlk{PDVizszN NVriNG1bW0GQR1XS
EFO-21 NV7ZZoVDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTqOXpKSzVyPUOzMlAxPSEQvF2= MoXCV2FPT0WU
HCC38 M1jaUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LZb2lEPTB;M{OuN|g1OSEQvF2= M3LJ[HNCVkeHUh?=
IA-LM NEi5OZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3iwb2lEPTB;M{OuO|g5QSEQvF2= MmCwV2FPT0WU
CTV-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfhUVFIUUN3ME2zN{46Pzh4IN88US=> M2KzOXNCVkeHUh?=
NCI-H446 MkfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTTb|hKSzVyPUO0MlI3QDlizszN NFW5ZXlUSU6JRWK=
IST-SL1 NHv0dVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrBSYxKSzVyPUO0Mlc1ODhizszN NVi5dVF6W0GQR1XS
EW-22 NWW4Rmx{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\jRmlEPTB;M{SuO|c2QSEQvF2= NGjKb4JUSU6JRWK=
JEG-3 MlLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIribo5KSzVyPUO2MlE4PjZizszN NXLOSWpPW0GQR1XS
LU-65 M3;temdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGK2ZYVKSzVyPUO2MlI6QDVizszN MYLTRW5ITVJ?
NCI-H596 NVHHbWsxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH2yT|BKSzVyPUO2Mlk2QTFizszN NFTneHhUSU6JRWK=
KNS-81-FD Moj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\IT4cyUUN3ME2zO{4yPDVizszN MVXTRW5ITVJ?
NCI-H1793 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnITWM2OD1|Nz63NFg3KM7:TR?= MV3TRW5ITVJ?
NCI-H460 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPYXWRKSzVyPUO4MlA5PzNizszN NW\vXoNNW0GQR1XS
MPP-89 NGDDcGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HrUWlEPTB;M{muOVg5PiEQvF2= M2nmPXNCVkeHUh?=
D-542MG M4f4TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFH5W4ZKSzVyPUO5Mlg1OzZizszN MXHTRW5ITVJ?
JAR NHG5em1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTETXVpUUN3ME20NE41PzB3IN88US=> NFXVPFdUSU6JRWK=
NCI-H209 NILRdIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jRXGlEPTB;NECuOlc4KM7:TR?= MY\TRW5ITVJ?
G-402 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrrZoVsUUN3ME20NU4{QTl|IN88US=> NIjYOnNUSU6JRWK=
IST-MES1 NIHq[XpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXm[Zg3UUN3ME20Nk4yQTN3IN88US=> MUfTRW5ITVJ?
Daoy NHrOT4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3np[2lEPTB;NEKuOVQ4OSEQvF2= M2juVXNCVkeHUh?=
EW-11 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTR|LkGyNVEh|ryP MXLTRW5ITVJ?
Saos-2 M2S4VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfGTWM2OD12Mz6xOVM4KM7:TR?= MXTTRW5ITVJ?
no-10 NXvJNFRNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlOxTWM2OD12Mz6xO|AzKM7:TR?= MWXTRW5ITVJ?
HCC1395 NHjrbFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjFSlJZUUN3ME20N{41PjR2IN88US=> M4HyfnNCVkeHUh?=
HCE-4 NYnNdotLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTR|Lke2OlQh|ryP NUW0TG4yW0GQR1XS
EW-1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLSZphKSzVyPUSzMlgxPDlizszN NX;ufFV6W0GQR1XS
OCUB-M NWDF[Gh6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvXbFdKSzVyPUS0MlM3OzhizszN MVjTRW5ITVJ?
IGR-1 NUP2UmI3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX74S5RzUUN3ME20OE41OTF3IN88US=> MVXTRW5ITVJ?
NCI-H1838 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PqcmlEPTB;NESuOFM1QSEQvF2= Mk\KV2FPT0WU
NCI-H2405 M36ydmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTR2LkWzOEDPxE1? MV;TRW5ITVJ?
GB-1 NIPYdVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfrPZBSUUN3ME20OE44PDZ|IN88US=> M3vVSHNCVkeHUh?=
MG-63 NYTRNpdDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHvXHpKSzVyPUS2MlA3QTZizszN MVnTRW5ITVJ?
KP-N-YN M2q1XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTR4LkS2O|kh|ryP MVrTRW5ITVJ?
no-11 M1jwZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{m2dWlEPTB;NEeuNFI1PCEQvF2= MV;TRW5ITVJ?
SW948 NUPqNJJlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXlcVB3UUN3ME20O{4{Ozd5IN88US=> MkTUV2FPT0WU
CAMA-1 Ml\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M170cmlEPTB;NEeuN|Q{QCEQvF2= NF;lcVBUSU6JRWK=
HCC1187 MnvrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2TCc2lEPTB;NEeuOVEh|ryP M3LkNnNCVkeHUh?=
D-392MG NIf4RW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jjN2lEPTB;NEeuOlUyPiEQvF2= MlXCV2FPT0WU
647-V MorhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2m2b2lEPTB;NEmuN|QyPCEQvF2= MWXTRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo Oral dosing of CI-1040 impairs the growth of colon tumor xenografts of mouse and human with a wide dose range of 48-200 mg/kg per dose, but not of P388 leukemia. [1] CI-1040 inhibits the tumor xenografts from PTC cells carrying a BRAF mutation with 31.3% reduction, carrying the RET/PTC1 rearrangement with 47.5% reduction than in untreated (vehicle) mice after 3 weeks of oral administration (300 mg/kg/d). No toxic effects are observed in any mice when they are treated with CI-1040. [2] Transient exposure of mammary tumors to CI-1040 and UCN-01 causes tumor cell death in vivo and prolonged suppression of tumor regrowth. Combined treatment with CI-1040 (25 mg/kg) and UCN-01 (0.1-0.2 mg/kg) significantly reduces MDA-MB-231, and largely abolishs MCF7 tumor growth in implanted athymic mice, while either single treatment has no significant activity. The drug combination leads to profound tumor cell death which correlates with a reduction in the phosphorylation of ERK1/2 and the immuno-reactivity of Ki67 and of CD31. [5]

Protocol

Kinase Assay:

[2]

+ Expand

MEK1 Assay:

MAP kinase is activated after phosphorylation by MEK; the activated MAP kinase subsequently phosphorylates myelin basic protein (MBP).Incorporation of 32P into myelin basic protein (MBP) is assayed in the presence of glutathione S-transferase (GST) fusion proteins containing the 44-kDa MAPK (GST-MAPK) or the 45-kDa MEK (GST-MEK1). Assays are conducted in 50μL of 50 mM Tris, pH 7.4/10 mM MgCl2 /2 mM EGTA/10 μM [γ-32P]ATP containing 10 μg of GST-MEK1, 0.5 μg of GST-MAPK, and 40 μg of MBP. After incubation at 30°C for 15 minutes, reactions are stopped by addition of Laemmli SDS sample buffer. Phosphorylated MBP is resolved by SDS/10% PAGE. This screening effort leads to the discovery of several small-molecule inhibitors of MEK, i.e. CI-1040. Experiments assessing the order of addition shows that CI-1040 directly inhibits MEK1 with a 50% inhibitory concentration (IC50) of 17 nM, without affecting the activity of MAPK.
Cell Research:

[1]

+ Expand
  • Cell lines: Colon 26 carcinoma cells
  • Concentrations: 0.1-10 μM
  • Incubation Time: 24 hours
  • Method:

    Cells are planted seeded in T-75 cm 2 flasks and treated the next day for 24 hous with either DMSO or CI-1040. Single-cell suspensions are collected, and pellets are fixed in ice-cold ethanol (70%) for 30 minutes. After centrifugation of the samples, propidium iodide (50 μg/mL) and RNase (30 units/mL) are added to the pellets for 20 minutes at 37 °C. After filtration, samples are analyzed by flow cytometry.


    (Only for Reference)
Animal Research:

[3]

+ Expand
  • Animal Models: PTC cells in athymic mice
  • Formulation: Cremophor EL–95% ethanol (50:50) and dilutes with water
  • Dosages: 150 mg/kg
  • Administration: Orally twice daily
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 96 mg/mL (200.55 mM)
Ethanol 14 mg/mL (29.24 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% PEG400+0.5% Tween80+5% propylene glycol, pH 9
For best results, use promptly after mixing.
10 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 478.67
Formula

C17H14ClF2IN2O2

CAS No. 212631-79-3
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00033384 Completed Breast Cancer|Colorectal Cancer|Lung Cancer|Pancreatic Cancer University of Alabama at Birmingham|National Cancer Institute (NCI) February 2002 Phase 2
NCT00033384 Completed Breast Cancer|Colorectal Cancer|Lung Cancer|Pancreatic Cancer University of Alabama at Birmingham|National Cancer Institute (NCI) February 2002 Phase 2
NCT00034827 Completed Colorectal Neoplasms|Breast Neoplasms|Carcinoma Non-Small-Cell Lung|Pancreatic Neoplasms Pfizer January 2002 Phase 2
NCT00034827 Completed Colorectal Neoplasms|Breast Neoplasms|Carcinoma Non-Small-Cell Lung|Pancreatic Neoplasms Pfizer January 2002 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

MEK Signaling Pathway Map

MEK Inhibitors with Unique Features

Related MEK Products4

Tags: buy PD184352 (CI-1040) | PD184352 (CI-1040) supplier | purchase PD184352 (CI-1040) | PD184352 (CI-1040) cost | PD184352 (CI-1040) manufacturer | order PD184352 (CI-1040) | PD184352 (CI-1040) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID